Efficacy and Safety of Eslicarbazepine Acetate as First Add-on to Levetiracetam or Lamotrigine Monotherapy or as Later Adjunctive Treatment for Subjects With Uncontrolled Partial-onset Seizures: A Multicenter, Open-label, Non-randomized Trial
Phase of Trial: Phase IV
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Eslicarbazepine acetate (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors Sunovion Pharmaceuticals
- 07 Jul 2017 Status changed from not yet recruiting to recruiting.
- 05 Jul 2017 Planned initiation date changed from 30 Jun 2017 to 7 Jul 2017.
- 19 Apr 2017 New trial record